Akut limfoid leukémia (ALL): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 122
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

1227 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES (ELI-ALL)

  Centre International de Recherche Sur Le Cancer· Lyon 7eme, Franciaország· EU contribution 6 502 240 EUR· until 2031. aug.· 12 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX (THANATOS)

  Commissariat A L Energie Atomique Et Aux Energies Alternatives· Paris, Franciaország· EU contribution 13 557 641 EUR· until 2031. aug.· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of RAS mutant subclones in the development of High Hyperdiploid B-ALL (RasWayToALL)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Science, Innovation, Health, Earth, And Life Technologies for ALL (SCIENCE4ALL)

  Istinye University· Istanbul, Törökország· EU contribution 350 000 EUR· until 2028. jún.

5 of 13 running projects, newest first. Listed amounts together: 62,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

  NCT06447987· City of Hope Medical Center· Frissítve: 2026. nov. 12.

  “Pending Interim Analysis”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  SPARK-ALL: Calaspargase Pegol in Adults With ALL

  NCT04817761· Institut de Recherches Internationales Servier· Frissítve: 2026. okt. 29.

  “Sponsor decision.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Pyronaridine in Acute Myeloid Leukemia (AML)

  NCT05291390· Armaceutica, Inc.· Frissítve: 2026. okt. 19.

  “Change of protocol”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

  NCT04920968· Maria Sklodowska-Curie National Research Institute of Oncology· Frissítve: 2026. okt. 15.

  “Following the recommendation of the Data Monitoring Committee (DMC), based on the results of the interim analysis, the Sponsor has decided to terminate the study prematurely”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Beijing Boren Hospital· Frissítve: 2026. okt. 15.

  “No participants.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

  NCT06195891· City of Hope Medical Center· Frissítve: 2026. okt. 15.

  “Timeline Adjustment”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home

  NCT06639958· Children's Oncology Group· Frissítve: 2026. okt. 5.

  “All potential pilot phase pts have been enrolled.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase

  NCT07320534· Gadjah Mada University· Frissítve: 2026. okt. 1.

  “Interim analysis showed no significant benefit of levofloxacin. Prolonged antibiotic use may increase adverse effects and resistance. Limited funding and the approaching end of the study period also supported early termination.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

  NCT06738368· University of Washington· Frissítve: 2026. szept. 29.

  “Safety Review”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

  NCT03494569· City of Hope Medical Center· Frissítve: 2026. szept. 28.

  “Accrual goal”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

  NCT04530565· National Cancer Institute (NCI)· Forrás

• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

  NCT04301076· National Cancer Institute (NCI)· Forrás

• A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

  NCT05621291· National Cancer Institute (NCI)· Forrás

• A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

  NCT07223021· Memorial Sloan Kettering Cancer Center· Forrás

• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  NCT03914625· National Cancer Institute (NCI)· Forrás

• Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT07572136· National Cancer Institute (NCI)· Forrás

• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT04546399· National Cancer Institute (NCI)· Forrás

• Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

  NCT01087333· National Cancer Institute (NCI)· Forrás

• Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

  NCT07387926· Novartis Pharmaceuticals· Forrás

• A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Merck Sharp & Dohme LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Diagnostic Concordance and Superiority of Flow Cytometry Over Immunohistochemistry in Acute Leukemia Immunophenotyping: A Single-Center Study.

  Med Sci Monit, 2026. aug.

• B-Acute Lymphoblastic Leukemia Masquerading as Multifocal Langerhans Cell Histiocytosis: a Diagnostic Paradigm Shift.

  Clin Lab, 2026. ápr.

• Utility of Immunocytochemistry in Cerebrospinal Fluid of B-ALL Patients for CNS Involvement: A Pilot Study.

  Cytopathology, 2026. márc.

• Mesothelin Expression in Acute Leukemia: Correlations With Immunophenotype, Cytogenetics, and Mutational Status.

  Appl Immunohistochem Mol Morphol, 2026. febr.

• Utility of flow cytometric PAX5 protein detection for the diagnosis of B-cell acute lymphoblastic leukemia.

  Clin Chem Lab Med, 2026. jan.

• Expression of the promyelocytic leukemia zinc-finger in T-lymphoblastic lymphoma and leukemia has strong implications for their cellular origin and greater association with initial bone marrow involvement.

  Mod Pathol, 2012. máj.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.